Global Blood Therapeutics, Inc. (GBT) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) from a hold rating to a buy rating in a research note published on Tuesday. They currently have $36.00 price target on the stock.

According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “

Other equities analysts have also issued research reports about the stock. BidaskClub raised shares of Global Blood Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 17th. Oppenheimer Holdings, Inc. began coverage on shares of Global Blood Therapeutics in a research report on Friday, August 4th. They set an outperform rating and a $53.00 price objective on the stock. Wedbush reaffirmed an ourperform rating and set a $73.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, September 18th. Cowen and Company reaffirmed an outperform rating and set a $83.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Finally, Needham & Company LLC assumed coverage on Global Blood Therapeutics in a report on Wednesday, September 20th. They set a buy rating and a $51.00 price target on the stock. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $54.08.

Shares of Global Blood Therapeutics (GBT) opened at 32.95 on Tuesday. The firm’s 50-day moving average is $28.91 and its 200 day moving average is $29.41. The stock’s market capitalization is $1.44 billion. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.06. During the same quarter in the prior year, the business posted ($0.58) EPS. On average, analysts expect that Global Blood Therapeutics will post ($2.44) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/11/global-blood-therapeutics-inc-gbt-upgraded-by-zacks-investment-research-to-buy.html.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction on Friday, July 21st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now owns 143,255 shares in the company, valued at $4,297,650. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Deval L. Patrick sold 27,053 shares of Global Blood Therapeutics stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total transaction of $803,203.57. Following the sale, the director now owns 12,053 shares in the company, valued at approximately $357,853.57. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,053 shares of company stock worth $1,073,204. 5.30% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Asset Management One Co. Ltd. bought a new position in shares of Global Blood Therapeutics during the first quarter valued at $130,000. Great West Life Assurance Co. Can bought a new position in shares of Global Blood Therapeutics during the first quarter valued at $129,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Global Blood Therapeutics by 694.9% during the second quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after acquiring an additional 3,975 shares during the period. Legal & General Group Plc lifted its holdings in shares of Global Blood Therapeutics by 10.1% during the first quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after acquiring an additional 440 shares during the period. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of Global Blood Therapeutics during the first quarter valued at $230,000. Hedge funds and other institutional investors own 86.07% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is develop

According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “

Other equities analysts have also issued research reports about the stock. BidaskClub raised shares of Global Blood Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 17th. Oppenheimer Holdings, Inc. began coverage on shares of Global Blood Therapeutics in a research report on Friday, August 4th. They set an outperform rating and a $53.00 price objective on the stock. Wedbush reaffirmed an ourperform rating and set a $73.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, September 18th. Cowen and Company reaffirmed an outperform rating and set a $83.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Finally, Needham & Company LLC assumed coverage on Global Blood Therapeutics in a report on Wednesday, September 20th. They set a buy rating and a $51.00 price target on the stock. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $54.08.

Shares of Global Blood Therapeutics (GBT) opened at 32.95 on Tuesday. The firm’s 50-day moving average is $28.91 and its 200 day moving average is $29.41. The stock’s market capitalization is $1.44 billion. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.06. During the same quarter in the prior year, the business posted ($0.58) EPS. On average, analysts expect that Global Blood Therapeutics will post ($2.44) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/11/global-blood-therapeutics-inc-gbt-upgraded-by-zacks-investment-research-to-buy.html.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction on Friday, July 21st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now owns 143,255 shares in the company, valued at $4,297,650. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Deval L. Patrick sold 27,053 shares of Global Blood Therapeutics stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total transaction of $803,203.57. Following the sale, the director now owns 12,053 shares in the company, valued at approximately $357,853.57. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,053 shares of company stock worth $1,073,204. 5.30% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Asset Management One Co. Ltd. bought a new position in shares of Global Blood Therapeutics during the first quarter valued at $130,000. Great West Life Assurance Co. Can bought a new position in shares of Global Blood Therapeutics during the first quarter valued at $129,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Global Blood Therapeutics by 694.9% during the second quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after acquiring an additional 3,975 shares during the period. Legal & General Group Plc lifted its holdings in shares of Global Blood Therapeutics by 10.1% during the first quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after acquiring an additional 440 shares during the period. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of Global Blood Therapeutics during the first quarter valued at $230,000. Hedge funds and other institutional investors own 86.07% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply